Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

1yr ago Hedge Fund hedgenordic Views: 535

Stockholm (HedgeNordic) – Max Mitteregger of Gladiator Fond has frequently voiced his concerns about the macroeconomic environment in recent years, pointing to the massive central bank money printing, and ever-increasing debt levels, among other developments. Mitteregger’s cautious stance, partly reflected in his fund’s low net market exposure, significantly hurt the performance of Gladiator Fond last year. His increasingly cautious stance helped long/short equity fund Gladiator Fond advance 12 percent in the first quarter of 2022.

“People think I’m always a little negative, but now all the alarm bells are ringing,” Max Mitteregger tells Swedish business magazine Dagens Industri (DI). “All alarm bells are ringing.” Mitteregger’s bearish and cautious stance stems from impending wage inflation on the back of rampant inflation and rising long-term interest rates. Russia’s war in Ukraine is also a major factor of concern for market participants, according to the money manager. “Globalization is dead now because of what is happening with Russia,” Mitteregger tells Dagens Industri.

“People think I’m always a little negative, but now all the alarm bells are ringing.”

Despite Gladiator Fond recouping some of last year’s loss of 51.4 percent, Max Mitteregger’s long/short equity fund will be merged with Adrigo Small & Midcap L/S under Adrigo’s management later this year. Following more than 17 years at the helm of Gladiator Fond, Mitteregger will continue to serve as Senior Advisor to East Capital Group’s Adrigo platform. Gladiator Fond has managed to generate an annualized return of 6.2 percent since launching in early 2005.

Although Max Mitteregger maintains a cautious view on the development of equity markets in the immediate future, he highlights three listed companies worth investing in. Both Mitteregger and his Gladiator Fond have high exposure to Swedish research-based biopharma companies Camarus and BioArctic, as well as a leading care company in the Nordics, Attendo. Gladiator Fond ended the month of March with a negative market exposure of 20 percent.

All Alarm Bells are Ringing on HedgeNordic.


Today's Hedge Fund Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.